Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis Authors:

Affiliations: 1 Centre for Health Economics and Medicines Evaluation, Bangor University, UK 2 Bristol Eye Hospital, Bristol, UK 3 Bristol Medical School, University of Bristol, UK 4 Institute of Translational Medicine, University of Liverpool, UK 5 UCL Institute of Ophthalmology and National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London Institute of Ophthalmology, UK 6 Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust, UK 7 University Hospitals Bristol NHS Foundation Trust, Bristol, UK

[1]  A. Dick,et al.  Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy , 2017, Pediatric Rheumatology.

[2]  A. Denniston,et al.  A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. , 2017, Health technology assessment.

[3]  Ashley P Jones,et al.  Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis , 2017, The New England journal of medicine.

[4]  İ. Tuğal-Tutkun,et al.  Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis , 2016, Turkish journal of ophthalmology.

[5]  K. Eames,et al.  Measuring Health Utilities in Children and Adolescents: A Systematic Review of the Literature , 2015, PloS one.

[6]  J. Brazier,et al.  Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.

[7]  Ashley P Jones,et al.  A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial) , 2014, Trials.

[8]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, PharmacoEconomics.

[9]  R. Edwards,et al.  EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[11]  Dmitri A. Jdanov,et al.  Human Mortality Database , 2019, Encyclopedia of Gerontology and Population Aging.

[12]  R. Rosenfeld,et al.  Authority , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[13]  Jeremy B Sussman,et al.  An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials , 2010, BMJ : British Medical Journal.

[14]  B. Thiers.  Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis , 2009 .

[15]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[16]  I. Foeldvari,et al.  Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. , 2005, The Journal of rheumatology.

[17]  W. Christen,et al.  Outcomes of Treatment with Immunomodulatory Therapy in Patients with Corticosteroid-Resistant Juvenile Idiopathic Arthritis-Associated Chronic Iridocyclitis , 2005, Ocular immunology and inflammation.

[18]  M. Boyle,et al.  Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.

[19]  H. Kautiainen,et al.  Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. , 2001, Ophthalmology.

[20]  A. Weiss,et al.  Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. , 1998, The Journal of pediatrics.